Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230111 | 0.85 | GRIN2B (0.48) | GRIN2BGPR119MMP2MMP9TEAD1 | |
| SCHEMBL2228463 | 0.84 | HRH2 (0.47) | GRIN2BGPR119MMP2MMP9HRH2 | |
| SCHEMBL2230044 | 0.84 | GRIN2B (0.46) | GRIN2BGPR119MMP2MMP9TEAD1 | |
| SCHEMBL2227687 | 0.83 | CHEK2 (0.47) | GRIN2BGPR119MMP2MMP9TEAD1 | |
| SCHEMBL2231126 | 0.83 | GRIN2B (0.44) | GRIN2BGPR119CYP3A4MMP2MMP9 | |
| SCHEMBL2365495 | 0.83 | GRIN2B (0.47) | GRIN2BGPR119MMP2MMP9TEAD1 | |
| SCHEMBL2229417 | 0.83 | GRIN2B (0.52) | GRIN2BCYP3A4SMN1; SMN2MMP2MMP9 | |
| SCHEMBL2227417 | 0.83 | GRIN2B (0.44) | GRIN2BGPR119MMP2MMP9TEAD1 | |
| SCHEMBL2363549 | 0.83 | GRIN2B (0.58) | GRIN2BCYP3A4SMN1; SMN2MMP2MMP9 | |
| SCHEMBL2229308 | 0.82 | GPR119 (0.44) | GRIN2BGPR119CYP3A4SMN1; SMN2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000010-B2 | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-04-07 | — | — | US | claimed |
| EP-2526100-B1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2013-12-04 | — | — | EP | claimed |
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-11-22 | — | — | US | claimed |
| WO-2011089550-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI AVENTIS (FR) | 2011-07-28 | — | — | WO | claimed |
| US-9000010-B2 | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2015-04-07 | — | — | US | disclosed |
| EP-2526100-B1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295909-A1 | ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | PRMT9, PRMT8, CBR1 | GRIN2B 362/4885GPR119 242/4885CYP3A4 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.